Yes, a 79-year-old should receive an annual COVID-19 vaccine.
Based on the 2025 ACIP recommendations, annual COVID-19 vaccination is part of the standard adult immunization schedule, and older adults aged ≥65 years face substantially higher risks from COVID-19, making vaccination particularly critical in this age group 1.
Why This Recommendation is Strong
Guideline Support
The Advisory Committee on Immunization Practices (ACIP) has incorporated COVID-19 vaccination into the 2025 adult immunization schedule with updated recommendations specifically addressing older adults 1. This represents the consensus position of CDC, American College of Physicians, American Academy of Family Physicians, and multiple other major medical organizations.
Disease Burden in This Age Group
Adults aged ≥65 years accounted for 67% of all COVID-19-associated hospitalizations during October 2023-January 2024, despite being a smaller proportion of the population 2. This disproportionate burden of severe disease makes vaccination especially important for mortality and morbidity reduction.
Vaccine Effectiveness Data
- Overall effectiveness: 75% (95% CI 70%-79%) against COVID-19-related hospitalization in adults ≥65 years 3
- Higher effectiveness (84%) in those who received the prior year's updated vaccine, demonstrating benefit from annual vaccination 3
- Vaccine efficacy in adults ≥65 years was 78.6% in clinical trials 4
Mortality Benefit
Vaccinated older adults hospitalized with COVID-19 had a 70% lower risk of in-hospital mortality (HR 0.30,95% CI 0.16-0.56) compared to unvaccinated patients, even after adjusting for frailty, comorbidities, and disease severity 5. This protective effect outweighed the increased baseline mortality risk associated with older age and greater frailty.
Safety Profile
The vaccines demonstrate an acceptable safety profile in older adults:
- No notable differences in safety profiles between adults ≥65 years and younger participants in clinical trials 4
- Most solicited adverse reactions were mild to moderate (pain/tenderness 60-66%, fatigue 37-42%, headache 28-29%) 4
- Grade 3 (severe) reactions were rare: pain 0.8-1.6%, fever 0.4-1.5% 4
Rare Adverse Events
A Swedish nationwide study of >2 million adults ≥65 years identified slightly increased risks for:
- Sudden sensorineural hearing loss (HR 1.43-1.61)
- Polymyalgia rheumatica (HR 1.14-1.16)
- Herpes zoster (HR 1.19-1.42 in sensitivity analysis)
However, these rare events do not alter the overall benefit-risk profile given the substantial mortality reduction 6.
Practical Implementation
Timing
- Annual vaccination should align with updated formulations targeting currently circulating variants
- For adults ≥65 years, ACIP recommended an additional dose of the 2023-2024 formula due to waning immunity and continued viral circulation 2
Special Consideration for Age 79
At 79 years old, this individual falls well within the age range where:
- COVID-19 hospitalization risk is highest
- Vaccine effectiveness remains robust (78.6% efficacy in ≥65 years group)
- Mortality benefit is most pronounced
- Safety profile is well-established
Common Pitfall to Avoid
Do not withhold vaccination due to frailty or multiple comorbidities. The mortality benefit of vaccination outweighs the increased baseline risk from these conditions 5. In fact, these factors make vaccination more important, not less.
The evidence consistently supports annual COVID-19 vaccination for a 79-year-old individual to reduce severe disease, hospitalization, and death 1, 4, 2, 5.